Eli Lilly Trulicity - Search News

GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front of it.

MarketWatch · 21h

Eli Lilly & Co. stock underperforms Friday when compared to competitors

Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow Jones Industrial Average DJIA falling 0.

Investing.com on MSN · 20h

Lilly Endowment sells $31.18 million in Eli Lilly stock

INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), has recently sold a significant portion of its holdings in the pharmaceutical giant. According to a recent SEC filing,

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

pharmaphorum15d

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

Eli Lilly’s crop of new products propelled the ... for the firm was likely the resilience of its diabetes blockbuster Trulicity. Trulicity (dulaglutide) grew more than expected to reach $1.2 ...

Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?

Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results